

British stomach cancer group trial IV: A randomised trial of cimetidine treatment in gastric cancer

Submission date 01/07/2001	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 01/07/2001	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 04/01/2012	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr - -

Contact details
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

Protocol serial number
GA3004

Study information

Scientific Title

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)**Health condition(s) or problem(s) studied**

Oesophagus, stomach cancer

Interventions

Patients are randomised to one of four treatment arms:

1. Arm A: Cimetidine 400 mg twice daily until death.
2. Arm B: Cimetidine 400 mg once daily until death.
3. Arm C: Placebo tablet twice daily until death.
4. Arm D: Placebo tablet once daily until death.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

cimeditine

Primary outcome(s)

Not provided at time of registration

Key secondary outcome(s))

Not provided at time of registration

Completion date

31/03/1995

Eligibility**Key inclusion criteria**

1. Biopsy proven adenocarcinoma of the stomach, any stage of disease, whether removed curatively or palliatively, or unresectable

2. Able to swallow tablets
3. No other concurrent cancer at other primary sites
4. No other serious illness, limiting prognosis severely

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex**Key exclusion criteria**

Not provided at time of registration

Date of first enrolment

01/01/1994

Date of final enrolment

31/03/1995

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

UKCCCR Register Co-ordinator

London

United Kingdom

NW1 2DA

Sponsor information

Organisation

Cancer Research UK (CRUK) (UK)

ROR

<https://ror.org/054225q67>

Funder(s)

Funder type

Industry

Funder Name

Cancer Research UK

Alternative Name(s)

CR_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Funder Name

Smithkline Beecham Pharmaceuticals

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/12/1999		Yes	No